Propanc Biopharma issues $67,860 convertible note with 35% conversion discount to 1800 Diagonal Lending

Propanc Biopharma, Inc.

Principal $67,860 for net $58,000; matures Apr 16, 2026; 15% one-time interest.
Conversion at 65% of lowest trading price in prior 10 days (35% discount); dilution risk.
Payments: $39,019.50 on Dec 15, 2025; then $9,754.88 on Jan 15, Feb 15, Mar 15, Apr 15, 2026.
Default triggers immediate acceleration; includes failure to pay, maintain OTC listing, or SEC reporting.
Proceeds for general working capital; note issued under Regulation D, not registered.

item 1.01item 2.03item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.